Filing Details

Accession Number:
0001209191-19-021014
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-22 17:01:17
Reporting Period:
2019-03-20
Accepted Time:
2019-03-22 17:01:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1690585 Magenta Therapeutics Inc. MGTA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1451612 Bruce Booth C/o Magenta Therapeutics, Inc.
100 Technology Sq, 5Th Floor
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-03-20 726,500 $0.00 4,117,125 No 4 J Indirect See Footnote
Common Stock Acquisiton 2019-03-20 14,245 $0.00 14,245 No 4 J Indirect See Footnote
Common Stock Disposition 2019-03-20 14,245 $17.86 0 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 J Indirect See Footnote
No 4 J Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund X, L.P. ("AVF X") to its general partner and limited partners without additional consideration.
  2. The shares are held directly by AVF X. The general partner of AVF X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVF X and AVA X LP, except to the extent of his pecuniary interest therein, if any.
  3. Represents the shares received by AVA X LP in connection with the pro rata distribution described in footnote 1 by AVF X.
  4. The shares are held directly by AVA X LP. AVA X LLC is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by AVF X and AVA X LP, except to the extent of his pecuniary interest therein, if any.
  5. The price reported in Column 4 is a weighted average price. These shares were sold by AVA X LP in multiple transactions at prices ranging from $17.75 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.